Source: HSJ
Area: News
In this article in the Health Service Journal, Michael Rawlins discusses the delay in accessing treatments approved by NICE, using the case of dexamethasone intravitreal implants (Ozurdex) for the treatment of retinal vein occlu…
Author: NeLM - Ophthalmology
Horizon scanning: FDA panel supports ocriplasmin for vitreomacular adhesion
Source: Reuters
Area: News
Reuter’s reports that a United States Food and Drug Administration (FDA) advisory panel has supported ocriplasmin (Jetrea®) as a treatment for vitreomacular adhesion, an age-related vision problem that can lead to blindnes…
Southern England Health Authority withdraws intravitreal bevacizumab policy following legal dispute
Source: Reuters
Area: News
According to a Reuters report, the Southampton, Hampshire, Isle of Wight and Portsmouth Primary Care Trust Cluster has discontinued its policy of offering intravitreal bevacizumab, an unlicensed but cheaper treatment for th…
Southern England Health Authority withdraws intravitreal bevacizumab policy following legal dispute
Source: Reuters
Area: News
According to a Reuters report, the Southampton, Hampshire, Isle of Wight and Portsmouth Primary Care Trust Cluster has discontinued its policy of offering intravitreal bevacizumab, an unlicensed but cheaper treatment for th…
CHMP recommends adoption of two new contra-indications for dexamethasone intravitreal implant (Ozurdex®)
Source: No information given
Area: News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the adoption of two new contraindications for Ozurdex® (dexamethasone…
NETAG reappraises bevacizumab (Avastin®) for diabetic macular oedema following appeal
Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) was requested to re-appraise bevacizumab (Avastin®) for the treatment of diabetic macular oedema in light of NICE not having recommended ran…
Cohort study: Stroke rates after introduction of bevacizumab and ranibizumab for AMD
Source: Ophthalmology
Area: News
A recent cohort study of Medicare patients concluded that vascular endothelial growth factor (VEGF)-inhibiting drugs for age-related macular degeneration (AMD) were not associated with an increased risk of stroke. How…
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: case-control study
Source: BMJ
Area: News
The development of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of age related macular degeneration (AMD). As VEGF functions in many physiological and pathological processes, including ma…
Antioxidant vitamin supplementation for preventing and slowing the progression of age-related cataract
Source: Cochrane
Area: Evidence > Drug Class Focused Reviews
Background
Age-related cataract is a major cause of visual impairment in the elderly. Oxidative stress has been implicated in its formation and progression. Antioxidant vitamin su…
Horizon scanning: Phase II study of FovistaTM and ranibizumab combination vs. ranibizumab monotherapy in wet AMD
Source: BioSpace
Area: News
Ophthotech Corporation has announced results from a prospective, randomised, controlled phase IIb trial of FovistaTM and ranibizumab combination therapy that show statistically significant superior efficacy over ranibizuma…
Review: Comparative effectiveness of anti-growth factor therapies for diabetic macular oedema
Source: Arch Internal Med
Area: News
This review outlines the clinical effectiveness and potential harms of off-label intravitreal administration of anti-VEGF drugs (pegaptanib, bevacizumab, ranibizumab, and aflibercept) for diabetic macular oedema.
Retrospective study: Risk of macular oedema among patients with type 2 diabetes treated with thiazolidinedione
Source: Arch Internal Med
Area: News
This retrospective study, using The Health Improvement Network (THIN) database, evaluated the short and long-term risks of developing diabetic macular oedema (DMO) among patients with type 2 diabetes who were treat…
SMC accepts restricted use of dexamethasone intravitreal implant (Ozurdex®) for macular oedema following branch retinal vein occlusion or central retinal vein occlusion
Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium (SMC) has accepted dexamethasone intravitreal implant (Ozurdex®) for restricted use within NHS Scotland for the treatment of adul…
Interventions for chronic blepharitis
Source: Cochrane Library
Area: Evidence > Disease Focused Reviews
Background Blepharitis, an inflammatory condition associated with itchiness, redness, flaking, and crusting of the eyelids, is a common eye condition that affects both children an…
Long-term stability of bevacizumab repackaged in 1 mL polypropylene syringes for intravitreal administration
Source: Annales Pharmaceutiques Francaises
Area: Evidence > Medicines Management > References
Introduction: The anti-angiogenic monoclonal antibody, bevacizumab, is currently used by intravitreal administration as an off-label drug to treat ag…
10-Minute Consultation: Blepharitis
Source: British Medical Journal (BMJ)
Area: News
This article forms one of a series of occasional articles on common problems in primary care. The current article focuses on blepharitis and begins with a case of a patient presenting to their GP. A dis…
One-year preliminary results from IVAN study shows ranibizumab and bevacizumab of similar efficacy for the treatment of neovascular AMD
Source: Ophthalmology
Area: News
One-year (preliminary) outcomes of the IVAN trial comparing ranibizumab with bevacizumab intravitreal injections for the treatment of neovascular age-related macular degeneration (AMD) have been published.
…
Squalamine eye drops granted fast track designation in the US for wet AMD
Source: BioSpace
Area: News
According to BioSpace, squalamine eye drops have been granted Fast Track designation by the US FDA for the potential treatment of the wet form of age-related macular degeneration (wet AMD).
Squalamine is s small…
Further results from Phase II study of VEGF Trap-Eye in diabetic macular oedema published
Source: Ophthalmology
Area: News
One-year results from the DA VINCI Phase II study evaluating aflibercept (VEGF Trap-Eye versus photocoagulation in the treatment of diabetic macular oedema (DMO) have been published early online in Ophthalmology.
&#…
Retrospective study: Topical antibiotics increase risk of endophthalmitis after intravitreal injections
Source: Ophthalmology
Area: News
This retrospective Canadian study examined the incidence of endophthalmitis (inflammatory condition of the intraocular cavities) following different antibiotic prophylaxis strategies for intravitreal injections of anti…